Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 1/2004

01-01-2004 | Original Paper

Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.

Authors: S. Samantaray, R. Sharma, T. K. Chattopadhyaya, S. Datta Gupta, R. Ralhan

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2004

Login to get access

Abstract

Purpose

Matrix metalloproteinases (MMPs) are known to play an important role in extracellular matrix remodeling during the process of tumor invasion and metastasis. However, little is known about their role in preinvasive lesions and early esophageal carcinomas.

Method

Immunohistochemical analysis of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) expression was carried out in paraffin-embedded sections of surgically resected esophageal squamous cell carcinoma (ESCC) (58 cases) and paired distal normal esophageal tissues (44 cases) and correlated with clinicopathological parameters.

Result

Overexpression of MMP-2 and MMP-9 proteins was observed in 39 (67%) and 32 (55%) of the 58 ESCCs, respectively localized in tumor cell cytoplasm and stromal elements. Histological evaluation of hematoxylin- and eosin-stained 44 matched distal normal esophageal tissue sections revealed that 26 comprised of normal epithelium, while 15 tissues showed evidence of dysplasia and three tissues showed hyperplasia. Interestingly, 12 (80%) and 13 (87%) of these 15 dysplasias showed immunostaining for MMP-2 and MMP-9 proteins, respectively. Low levels of MMP-2 and MMP-9 were observed in 10 (38%) and 6 (23%) of 26 matched histologically normal esophageal tissues, respectively. Higher MMP-2 immunopositivity was observed in well and moderately differentiated SCCs in comparison with poorly differentiated tumors. The expression of MMP-2 was significantly reduced with the progressive de-differentiation of esophageal SCCs (P =0.03). Overexpression of MMP-2 and MMP-9 in dysplasia as well as SCC suggests that these alterations occur in early stages of esophageal tumorigenesis.

Conclusion

Increased levels of MMP-2 and MMP-9 proteins in ESCCs as compared to normal esophageal tissues suggest their association with esophageal tumorigenesis. Increased levels of these MMPs are observed in majority of dysplasias analyzed herein, indicating that these alterations may be early events in esophageal tumorigenesis. In-depth studies are warranted to determine their role in development and progression of esophageal cancer.
Literature
1.
go back to reference Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC (1997) Matrix metalloproteinases as stromal effectors of human carcinoma progression therapeutical implications. Matrix Biol 15:535–541CrossRefPubMed Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC (1997) Matrix metalloproteinases as stromal effectors of human carcinoma progression therapeutical implications. Matrix Biol 15:535–541CrossRefPubMed
2.
go back to reference Chambers AF, Matrisian LM (1997) Changing view of the role of matrix metalloproteinases in metastasis. J Natl. Cancer Inst 89:1260–1270CrossRef Chambers AF, Matrisian LM (1997) Changing view of the role of matrix metalloproteinases in metastasis. J Natl. Cancer Inst 89:1260–1270CrossRef
3.
go back to reference Chen PS, Zhai WR, Zhou XM, Zhang JS, Zhang YE, Ling YQ, Gu YH (2001) Effects of hypoxia, hyperoxia on the regulation of expression and activity of matrix metalloproteinase-2 in hepatic stellate cells. World J Gastroenterol 7:647–651PubMed Chen PS, Zhai WR, Zhou XM, Zhang JS, Zhang YE, Ling YQ, Gu YH (2001) Effects of hypoxia, hyperoxia on the regulation of expression and activity of matrix metalloproteinase-2 in hepatic stellate cells. World J Gastroenterol 7:647–651PubMed
4.
go back to reference Colby TV, Bennett W, Harris CC, Stetler-Stevenson WG, Liotta L, Ferrans VJ, Travis WD (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 31:296–305PubMed Colby TV, Bennett W, Harris CC, Stetler-Stevenson WG, Liotta L, Ferrans VJ, Travis WD (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 31:296–305PubMed
5.
go back to reference Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, HAnby A, Balkwill F (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365–5369PubMed Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, HAnby A, Balkwill F (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365–5369PubMed
6.
go back to reference Dong Z, Kumar R, Yang X, Fidller IJ (1997) Macrophage derived metalloelastase is responsible for generation of angiostatin in Lewis lung carcinoma. Cell 88:801–810PubMed Dong Z, Kumar R, Yang X, Fidller IJ (1997) Macrophage derived metalloelastase is responsible for generation of angiostatin in Lewis lung carcinoma. Cell 88:801–810PubMed
7.
go back to reference Galateau-Salle FB, Luna RE, Horiba K, Sheppard MN, Hayashi T, Fleming MV, Colby TV, Bennett W, Harris CC, Stetler-Stevenson WG, Liotta L, Ferrans VJ, Travis WD (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 3:296–305 Galateau-Salle FB, Luna RE, Horiba K, Sheppard MN, Hayashi T, Fleming MV, Colby TV, Bennett W, Harris CC, Stetler-Stevenson WG, Liotta L, Ferrans VJ, Travis WD (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 3:296–305
8.
go back to reference Hart IR, Saini A (1992) Biology of tumour metastasis. Lancet 339:1453–1457PubMed Hart IR, Saini A (1992) Biology of tumour metastasis. Lancet 339:1453–1457PubMed
9.
go back to reference Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337–344PubMed Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337–344PubMed
10.
go back to reference Johnsen M, Lund LR, Romer J, Almholt K, Dano K (1998) Cancer invasion and tissues remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10:667–671CrossRefPubMed Johnsen M, Lund LR, Romer J, Almholt K, Dano K (1998) Cancer invasion and tissues remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10:667–671CrossRefPubMed
11.
go back to reference Kohn EC, Liotta LA (1995) Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55:1856–1862PubMed Kohn EC, Liotta LA (1995) Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55:1856–1862PubMed
12.
go back to reference Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fuji Y (2000) Gelatinolytic activity of matrix metalloproteinase-2 and −9 in oesophageal carcinoma; a study using in situ zymography. Eur J Cancer 36:2164–2170CrossRefPubMed Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fuji Y (2000) Gelatinolytic activity of matrix metalloproteinase-2 and −9 in oesophageal carcinoma; a study using in situ zymography. Eur J Cancer 36:2164–2170CrossRefPubMed
13.
go back to reference Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA Cancer J Clin 49:8–31PubMed Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA Cancer J Clin 49:8–31PubMed
14.
go back to reference Lijnen HR, Ugwu F, Bini A, Collen D (1998) Generation of angiostatin-like fragment from plasminogen by stromelysin-1. Biochemistry 37:4699–4702CrossRefPubMed Lijnen HR, Ugwu F, Bini A, Collen D (1998) Generation of angiostatin-like fragment from plasminogen by stromelysin-1. Biochemistry 37:4699–4702CrossRefPubMed
15.
go back to reference Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE (1998) Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 43:791–797PubMed Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE (1998) Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 43:791–797PubMed
16.
go back to reference Naylor MS, Stamp GW, Davies BD, Balkwill FR (1994) Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 58:50–56PubMed Naylor MS, Stamp GW, Davies BD, Balkwill FR (1994) Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 58:50–56PubMed
17.
go back to reference O-Cheroenrat P, Rhys-Evans PH, Eccles SA (2001) Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127:813–820PubMed O-Cheroenrat P, Rhys-Evans PH, Eccles SA (2001) Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127:813–820PubMed
18.
go back to reference Ohashi K, Nemoto T, Nakamura K, Nemori R (2000) Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 88:2201–2209PubMed Ohashi K, Nemoto T, Nakamura K, Nemori R (2000) Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 88:2201–2209PubMed
19.
go back to reference Patterson BC, Sang QA (1997) Angiostatin conveting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272:28823–28825CrossRefPubMed Patterson BC, Sang QA (1997) Angiostatin conveting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272:28823–28825CrossRefPubMed
20.
go back to reference Remade AG, Neol A, Duggan C, McDermott E, Higgins NO, Foidart JM, Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77:926–931PubMed Remade AG, Neol A, Duggan C, McDermott E, Higgins NO, Foidart JM, Duffy MJ (1998) Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77:926–931PubMed
21.
go back to reference Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M (1999) Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 80:1366–1372CrossRefPubMed Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M (1999) Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 80:1366–1372CrossRefPubMed
22.
go back to reference Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, Morimatsu M (1992) Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer 70:2747–2753PubMed Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, Morimatsu M (1992) Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer 70:2747–2753PubMed
23.
go back to reference Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, Kano M (1999) Prognostic factors of esophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 80:1281–1288CrossRefPubMed Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, Kano M (1999) Prognostic factors of esophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 80:1281–1288CrossRefPubMed
24.
go back to reference Sobin LH, Flemming ID (1997) TNM classification of malignant tumors, 5th edn. Union Internationale Centre le cancer and the American Joint Committee on Cancer. Cancer 80:1803–1804PubMed Sobin LH, Flemming ID (1997) TNM classification of malignant tumors, 5th edn. Union Internationale Centre le cancer and the American Joint Committee on Cancer. Cancer 80:1803–1804PubMed
25.
go back to reference Sternlicht MD, Lotcher A, Sympson CJ, Huey B, rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z (1999) The stomal proteinase MMP3/Stromelysin-1 promotes mammary carcinogenesis. Cell 98:137–146PubMed Sternlicht MD, Lotcher A, Sympson CJ, Huey B, rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z (1999) The stomal proteinase MMP3/Stromelysin-1 promotes mammary carcinogenesis. Cell 98:137–146PubMed
26.
go back to reference Stetler-Stevenson WG, Liotta LA, Kliener DE (1993) Extracellular Matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434–1441PubMed Stetler-Stevenson WG, Liotta LA, Kliener DE (1993) Extracellular Matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 7:1434–1441PubMed
27.
go back to reference Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, Sorsa T, Salo T (1998) Expression of matrix metalloproteinases (MMP-1 and −2) and their inhibitors (TIMP-1, -2 and −3) in oral lichen planus, dysplasia, squamous cell carcinoma, and lymph node metastasis. Br J Cancer 77:2239–2245PubMed Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, Sorsa T, Salo T (1998) Expression of matrix metalloproteinases (MMP-1 and −2) and their inhibitors (TIMP-1, -2 and −3) in oral lichen planus, dysplasia, squamous cell carcinoma, and lymph node metastasis. Br J Cancer 77:2239–2245PubMed
28.
go back to reference Suzuki T, Kuwabara Y, Iwata H, Mitani M, Shinoda N, Sato A, Mitsui A, Sugiura M, Kato J, Fujii Y (2001) Role of matrix metalloproteinase-9 in in vitro invasion of esophageal carcinoma cells. J Surg Oncol 81:80–86CrossRef Suzuki T, Kuwabara Y, Iwata H, Mitani M, Shinoda N, Sato A, Mitsui A, Sugiura M, Kato J, Fujii Y (2001) Role of matrix metalloproteinase-9 in in vitro invasion of esophageal carcinoma cells. J Surg Oncol 81:80–86CrossRef
29.
go back to reference Talvensaari A, Apaja-Saekkinen M, Hoyhtya M, Westerlund A, Puistola U, Turpeenniemi T (1999) Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol 72:306–311CrossRefPubMed Talvensaari A, Apaja-Saekkinen M, Hoyhtya M, Westerlund A, Puistola U, Turpeenniemi T (1999) Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol 72:306–311CrossRefPubMed
30.
go back to reference Tryggvason K, Hoyhta M, Pyke M (1993) Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24:209–218PubMed Tryggvason K, Hoyhta M, Pyke M (1993) Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24:209–218PubMed
31.
go back to reference Uria JA, Lopez-Otin C (2000) Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 60:4745–4751PubMed Uria JA, Lopez-Otin C (2000) Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 60:4745–4751PubMed
32.
go back to reference Visscher DW, Hoyhtya M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R (1994) Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59:339–344PubMed Visscher DW, Hoyhtya M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R (1994) Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59:339–344PubMed
33.
go back to reference Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M, Imai K (1999) Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59:3313–3316PubMed Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M, Imai K (1999) Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59:3313–3316PubMed
34.
go back to reference Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K (2001) The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 84:276–282CrossRefPubMed Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K (2001) The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 84:276–282CrossRefPubMed
35.
go back to reference Yu Q, Stamenkovic I (2000) Cell surface localized matrix metalloproteinase-9 proteolytically activatesTGF-β and promotes tumor invasion and angiogenesis. Genes Dev 15:163–176 Yu Q, Stamenkovic I (2000) Cell surface localized matrix metalloproteinase-9 proteolytically activatesTGF-β and promotes tumor invasion and angiogenesis. Genes Dev 15:163–176
Metadata
Title
Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.
Authors
S. Samantaray
R. Sharma
T. K. Chattopadhyaya
S. Datta Gupta
R. Ralhan
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2004
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-003-0500-4

Other articles of this Issue 1/2004

Journal of Cancer Research and Clinical Oncology 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.